Is Amgen’s bispecific lung cancer drug becoming a global standard after chemotherapy failure?
Amgen’s Imdylltra has European approval in relapsed small cell lung cancer. Survival data now face reimbursement and adoption tests.
Why Merck’s CHMP win for KEYTRUDA plus Padcev matters in muscle-invasive bladder cancer
Merck’s bladder cancer push is moving earlier in Europe. KEYTRUDA plus Padcev could reset cisplatin-ineligible MIBC care.
Could Agios and Avanzanite turn PYRUKYND into Europe’s next rare blood disease launch test?
PYRUKYND has EU approval in thalassaemia. Now Agios and Avanzanite face Europe’s harder test: access, uptake and reimbursement.
EU backs Pfizer’s Hympavzi for hemophilia patients with inhibitors. What changes now?
Hemophilia care is moving beyond factor replacement. Pfizer’s Hympavzi EU expansion tests how far anti-TFPI therapy can scale.
Why Bristol Myers Squibb’s Sotyktu approval could reshape the oral psoriatic arthritis race
A new EU approval is only the first hurdle. Sotyktu now faces Europe’s tougher test: payer access, sequencing, and real-world uptake.
Does Rhythm Pharmaceuticals, Inc. now lead the rare neuroendocrine obesity treatment space?
Discover how Rhythm Pharmaceuticals, Inc.’s EU approval of setmelanotide could redefine rare obesity treatment and what comes next for the market.
How Merck’s ENFLONSIA could challenge existing infant RSV prevention pathways in Europe
European Union approval gives Merck’s ENFLONSIA a new opening in infant RSV prevention. Read what it means for rollout, reimbursement, and competition.
Meiji Seika Pharma wins EU orphan drug status for morcamilast in palmoplantar pustulosis
EU orphan status for morcamilast in PPP reshapes Meiji Seika Pharma’s European strategy. See what it means for PDE4 competition and rare dermatology.
Novo Nordisk secures EU nod for higher Wegovy dose amid intensifying GLP-1 competition
EU approves 7.2 mg Wegovy for obesity. Explore what this means for efficacy, competition and reimbursement across Europe.
Can EU-backed CDMO projects redefine pharma supply chains in post-industrial Europe?
The European Commission’s recent approval of €47 million in German state aid for Vetter Pharma’s new aseptic filling facility in Saarlouis marks more than a regional win. It signals a structural shift in how Europe views contract manufacturing organizations, or CDMOs—not merely as outsourcing vendors, but as core pillars of supply chain resilience, regional economic […]